Published in:
01-05-2013 | Symposium: Special Considerations for TKA in Asian Patients
No Better Flexion or Function of High-flexion Designs in Asian Patients With TKA
Authors:
Jong-Keun Seon, MD, Ji-Hyeon Yim, MD, Hyoung-Yeon Seo, MD, Eun-Kyoo Song, MD
Published in:
Clinical Orthopaedics and Related Research®
|
Issue 5/2013
Login to get access
Abstract
Background
Recently, high-flexion PCL-retaining (CR) and -substituting (PS) knee prostheses were designed to allow greater and safer flexion after TKA. However, the advantages of high-flexion TKA over standard design have been debated in terms of early maximal flexion. A recent study reported a high incidence of early loosening of the femoral component related to the deep flexion provided by high-flexion PS TKA.
Questions/Purposes
We determined whether high-flexion fixed bearing CR and PS prostheses would provide (1) a better flexion, (2) a better function, and (3) a higher incidence of radiographic loosening than TKA performed using standard fixed bearing CR prostheses in Asian patients.
Methods
From a total of 182 patients with primary unilateral TKA, we retrospectively reviewed 137 TKAs: 47 with high-flexion CR, 42 with high-flexion PS, and 48 with standard CR designs. ROM, Knee Society scores, and WOMAC scores were evaluated and compared among the three groups. Radiographically, we assessed radiolucent zones and component loosening. Minimum followup was 5 years (mean, 6.2 years; range, 5–8 years).
Results
We found no differences among the three groups in mean maximal flexion (high-flexion CR: 135°; high-flexion PS: 134°; standard CR: 136°), Knee Society scores, and WOMAC scores at last followup. Also, there were no differences among the three groups in terms of radiolucent lines around the prosthesis. No patient in any group had loosening of the femoral component.
Conclusions
The high-flexion CR or PS design had no advantages over the standard CR design with respect to ROM, clinical scores, and radiolucent lines around the femoral or tibial component after 5 years’ followup.
Level of Evidence
Level III, therapeutic study. See Instructions for Authors for a complete description of levels of evidence.